Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.

@article{Mulders2009VascularEG,
  title={Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms.},
  author={Peter F A Mulders},
  journal={BJU international},
  year={2009},
  volume={104 11},
  pages={1585-9}
}
Renal cell carcinoma (RCC) is among the most resistant tumours to chemotherapy, radiotherapy and hormonal therapy. Cytokine therapy is effective in a small subset of patients, but it is associated with substantial toxicity and rarely benefits patients with extensive tumour burdens or adverse prognostic factors. Since 2005, clinical trials have shown significant clinical benefits for five molecularly targeted therapies in patients with advanced RCC. These agents constitute two mechanistic… CONTINUE READING
17 Citations
35 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

Effect of temsirolimus versus interferonalpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

  • Dutcher JPSP, D McDermott
  • Med Oncol
  • 2009

Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poorrisk features . ASCO Annual Meeting Proceedings 2008

  • T Logan, D McDermott, J Dutcher
  • J Clin Oncol
  • 2009

Overall survival with sunitinib versus interferon ( IFN )alfa as first - line treatment of metastatic renal cell carcinoma ( mRCC ) . 2008 ASCO Annual Meeting Proceedings

  • RA Figlin, TE Hutson, P Tomczak
  • J Clin Oncol
  • 2009

Phase I / II : trial of CCI779 and bevacizumab in stage IV renal cell carcinoma : phase I safety and activity results

  • Merchan, G Liu, T Fitch
  • J Clin Oncol
  • 2009

Similar Papers

Loading similar papers…